Retatrutide, a groundbreaking dual-acting glucose-dependent incretin mimetic, represents a significant advance in peptide treatments for the management of type 2 diabetic conditions and, increasingly, obesity. Unlike many existing therapeutic interventions, retatrutide integrates the actions of a GLP-1 receptor agonist and a GIP receptor agonist, o